Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...
News
Soccer pros may face increased risk of death from neurodegenerative disease
Mortality associated with neurodegenerative disease was higher, and mortality associated with other causes lower, among former pro soccer players...
News
Adding veliparib to chemotherapy improves PFS in BRCA-mutated breast cancer
BARCELONA – Adding veliparib to chemotherapy improved PFS and provided more durable benefit than did chemotherapy...
News
Veliparib improves PFS in high-grade serous epithelial ovarian cancer
BARCELONA – Adding veliparib to frontline CT and maintenance significantly extended PFS in women with high-grade...
News
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.
News
Nivolumab boosts overall survival in HCC
BARCELONA – Nivolumab led to clinically meaningful, but not statistically significant, improvement in OS and ORR vs. sorafenib for first-line...
News
PRIMA study: Niraparib maintenance improves PFS in advanced OC
BARCELONA – Niraparib improves PFS when given after first-line chemotherapy for advanced ovarian cancer, according...
News
mIDH1 inhibitor ivosidenib improves progression-free survival in advanced cholangiocarcinoma
BARCELONA - The first-in-class oral inhibitor of mIDH1, significantly improved PFS for advanced cholangiocarcinoma in the global, randomized,...
News
MONARCH 2: Abemaciclib plus fulvestrant improves overall survival
BARCELONA – MONARCH 2 trial data show that adding the CDK4/6 inhibitor abemaciclib to fulvestrant significantly improves overall survival in HR+,...
News
PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer
BARCELONA – Benefit was particularly pronounced in patients with a tumor BRCA mutation and those with homologous recombination deficiency (HRD)–...
News
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
News
CheckMate 817: Nivo+ipi shows safety, efficacy across stage IV NSCLC subgroups
BARCELONA – Combination nivolumab and ipilimumab showed good safety and encouraging clinical activity in patients with advanced NSCLC, despite...
News
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
News
Cancer drug prices higher in U.S. than Europe; don’t correlate with clinical benefit
BARCELONA – Cancer drug prices are significantly higher in the United states than in Europe, and they don’t correlate with clinical benefit in...